Breaking News Instant updates and real-time market news.

NTNX

Nutanix

$51.48

2.385 (4.86%)

07:48
03/13/18
03/13
07:48
03/13/18
07:48

Nutanix price target raised to $58 from $50 at RBC Capital

RBC Capital analyst Matthew Hedberg raised his price target on Nutanix to $58 after the company's Investor Day presentation forecast a billings expansion to reach $3B by FY21. Hedberg notes that the company's position as a "disruptive force in cloud computing" offering technology that leads to above-average growth and margin expansion gives him confidence in Nutanix strategy to achieve its forecasts. The analyst keeps his Outperform rating, adding that the shift toward recurring revenues from the company's growing software business is not reflected in the valuation.

NTNX Nutanix
$51.48

2.385 (4.86%)

03/13/18
NEED
03/13/18
NO CHANGE
Target $61
NEED
Buy
Nutanix price target raised to $61 from $48 at Needham
Needham analyst Jack Andrews raised his price target on Nutanix to $61 after the company's Investor Day unveiled a 2021 billings target of $3B, assuming "historical expansion rates" for non-global and global customers. Andrews keeps his Buy rating, adding that the company's potential expansion of its upselling opportunity could produce expansion rates that are higher than historical patterns, yielding even more impressive long-term results than those derived in yesterday's model for appliance-based consumption.
03/13/18
OPCO
03/13/18
NO CHANGE
Target $65
OPCO
Outperform
Nutanix price target raised to $65 from $43, a '2018 Top Pick' at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target on Nutanix to $65 from $43 following the company's investor day in New York. In a research note to investors, Kidron called Nutanix a "2018 Top Pick," and that he came away from the investor day event "impressed" with the company's positioning, vision -- which he called "very ambitious yet differentiated -- and market opportunity potential. Even with the strong move in the shares, the analyst sees further multiple expansion and plenty of upside ahead.
03/13/18
JMPS
03/13/18
NO CHANGE
Target $60
JMPS
Outperform
Nutanix price target raised to $60 at JMP Securities after investor day
Following Nutanix's analyst day meeting, JMP Securities analyst Erik Suppiger noted that the company announced an FY21 billings target of $3B, which he believes reflects a "confident" team executing on a "substantial" opportunity. Nutanix also unveiled a long-term product strategy that Suppiger said he thinks is "strategically attractive." To reflect increased valuation multiples in the space as well as his expectations for higher growth, the analyst raised his price target on Nutanix to $60 from $45 and keeps an Outperform rating on the shares.
03/13/18
STFL
03/13/18
NO CHANGE
Target $52
STFL
Buy
Stifel more confident in Nutanix following company's first analyst day
After attending Nutanix's "well-attended" inaugural analyst day, Stifel analyst Brad Reback said he came away incrementally more confident in its strategy and model and still believes secular and company-specific factors can drive healthy top-line growth in coming years. Reback keeps a Buy rating and $52 price target on Nutanix shares.

TODAY'S FREE FLY STORIES

RSAIF

RSA Insurance

$0.00

(0.00%)

05:47
12/10/18
12/10
05:47
12/10/18
05:47
Upgrade
RSA Insurance rating change  »

RSA Insurance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWDHF

Skyworth Digital

$0.00

(0.00%)

05:45
12/10/18
12/10
05:45
12/10/18
05:45
Downgrade
Skyworth Digital rating change  »

Skyworth Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$40.72

-2.17 (-5.06%)

05:44
12/10/18
12/10
05:44
12/10/18
05:44
Hot Stocks
Biohaven announces initial 'positive' results from ongoing rimegepant study »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$73.87

0.1 (0.14%)

, GSK

GlaxoSmithKline

$37.28

-0.125 (-0.33%)

05:42
12/10/18
12/10
05:42
12/10/18
05:42
Downgrade
Tesaro, GlaxoSmithKline rating change  »

Tesaro downgraded to…

TSRO

Tesaro

$73.87

0.1 (0.14%)

GSK

GlaxoSmithKline

$37.28

-0.125 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWARF

Norwegian Air Shuttle

$0.00

(0.00%)

05:40
12/10/18
12/10
05:40
12/10/18
05:40
Upgrade
Norwegian Air Shuttle rating change  »

Norwegian Air Shuttle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASX

ASE Technology

$3.77

-0.06 (-1.57%)

05:39
12/10/18
12/10
05:39
12/10/18
05:39
Earnings
ASE Technology reports November revenue down 3.2% to $1.23B »

Reports November IC-atm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$18.42

0.41 (2.28%)

05:38
12/10/18
12/10
05:38
12/10/18
05:38
Periodicals
Rice Energy brothers want to take over running EQT, WSJ reports »

Derek and Toby Rice, who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ALNY

Alnylam

$74.28

-5.45 (-6.84%)

05:37
12/10/18
12/10
05:37
12/10/18
05:37
Hot Stocks
Alnylam announces settlement with Silence Therapeutics »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$53.08

-0.16 (-0.30%)

05:36
12/10/18
12/10
05:36
12/10/18
05:36
Hot Stocks
Bristol-Myers enters new clinical collaboration with Vedanta Biosciences »

Bristol-Myers and Vedanta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Dec

  • 24

    Jan

  • 20

    May

QDEL

Quidel

$48.48

-12.835 (-20.93%)

05:35
12/10/18
12/10
05:35
12/10/18
05:35
Conference/Events
Quidel to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

IQ

iQIYI

$18.51

-1.34 (-6.75%)

, CHL

China Mobile

$49.28

0.61 (1.25%)

05:34
12/10/18
12/10
05:34
12/10/18
05:34
Hot Stocks
iQIYI signs partnership with China Mobile »

iQIYI (IQ) recently…

IQ

iQIYI

$18.51

-1.34 (-6.75%)

CHL

China Mobile

$49.28

0.61 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$48.48

-12.835 (-20.93%)

05:27
12/10/18
12/10
05:27
12/10/18
05:27
Recommendations
Quidel analyst commentary  »

Quidel shares likely flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:24
12/10/18
12/10
05:24
12/10/18
05:24
Hot Stocks
Roche CEO Daniel O'Day to step down, Genentech CEO William Anderson to succeed »

Roche (RHHBY) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

EA

Electronic Arts

$82.57

-1.29 (-1.54%)

05:22
12/10/18
12/10
05:22
12/10/18
05:22
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

05:21
12/10/18
12/10
05:21
12/10/18
05:21
Hot Stocks
Gilead appoints Roche CEO Daniel O'Day as CEO, chairman »

Gilead Sciences announced…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

FIVE

Five Below

$95.53

-6.19 (-6.09%)

05:16
12/10/18
12/10
05:16
12/10/18
05:16
Upgrade
Five Below rating change  »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMXAY

Genmab

$0.00

(0.00%)

05:12
12/10/18
12/10
05:12
12/10/18
05:12
Upgrade
Genmab rating change  »

Genmab upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

05:10
12/10/18
12/10
05:10
12/10/18
05:10
Upgrade
UCB rating change  »

UCB upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTUY

Swedish Orphan Biovitrum

$0.00

(0.00%)

05:08
12/10/18
12/10
05:08
12/10/18
05:08
Upgrade
Swedish Orphan Biovitrum rating change  »

Swedish Orphan Biovitrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06
Upgrade
MorphoSys, Johnson & Johnson rating change  »

MorphoSys upgraded to Buy…

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

SLG

SL Green Realty

$93.32

-2.41 (-2.52%)

05:02
12/10/18
12/10
05:02
12/10/18
05:02
Upgrade
SL Green Realty rating change  »

SL Green Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$74.07

-1.04 (-1.38%)

04:59
12/10/18
12/10
04:59
12/10/18
04:59
Downgrade
Comerica rating change  »

Comerica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

PII

Polaris Industries

$88.44

-2.37 (-2.61%)

04:58
12/10/18
12/10
04:58
12/10/18
04:58
Downgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MPX

Marine Products

$21.59

-0.21 (-0.96%)

04:56
12/10/18
12/10
04:56
12/10/18
04:56
Downgrade
Marine Products rating change  »

Marine Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$67.58

-4.1 (-5.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.